{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:02:51Z","timestamp":1779951771019,"version":"3.53.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13555-026-01729-7","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:18:06Z","timestamp":1774963086000},"page":"2525-2540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA Study"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04780516","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Igor","family":"Snast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Valdman-Grinshpoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naji","family":"Bathish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Matz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Shclar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Czarnowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-6316","authenticated-orcid":false,"given":"Eran","family":"Shavit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbal Piller","family":"Maor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaf","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiran Naftalberg","family":"Blonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raanan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bleterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Barak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8400-9587","authenticated-orcid":false,"given":"Lev","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"12","key":"1729_CR1","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/jdv.15065","volume":"32","author":"A Armstrong","year":"2018","unstructured":"Armstrong A, Jarvis S, Boehncke WH, Rajagopalan M, Fern\u00e1ndez-Pe\u00f1as P, Romiti R, et\u00a0al. Patient perceptions of clear\/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear about Psoriasis worldwide survey. J Eur Acad Dermatol Venereol. 2018;32(12):2200\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1729_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/ijp.IJP_166_16","volume":"49","author":"VV Karamata","year":"2017","unstructured":"Karamata VV, Gandhi AM, Patel PP, Sutaria A, Desai MK. A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life. Indian J Pharmacol. 2017;49(1):84.","journal-title":"Indian J Pharmacol"},{"issue":"6","key":"1729_CR3","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1111\/bjd.16702","volume":"179","author":"P Jensen","year":"2018","unstructured":"Jensen P, Zachariae C, Skov L, Zachariae R. Sleep disturbance in psoriasis: a case\u2010controlled study. Br J Dermatol. 2018;179(6):1376\u201384.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1729_CR4","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/jdv.14868","volume":"32","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Papp KA, Lynde CW. Shifting the focus\u2014the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1729_CR5","doi-asserted-by":"publisher","unstructured":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use FINLAY 1994 Clinical and Experimental Dermatology Wiley Online Library [Internet]. [cited 2025 Dec 7]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"issue":"5","key":"1729_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/09546634.2019.1709612","volume":"31","author":"AM Rentz","year":"2020","unstructured":"Rentz AM, Skalicky AM, Esser D, Zema C, Becker K, Bodhani A, et\u00a0al. Reliability, validity, and the ability to detect change of the Psoriasis Symptom Scale (PSS) in patients with plaque psoriasis. J Dermatolog Treat. 2020;31(5):460\u20139.","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"1729_CR7","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/jdv.14254","volume":"31","author":"A Finlay","year":"2017","unstructured":"Finlay A. Broader concepts of quality of life measurement, encompassing validation. J Eur Acad Dermatol Venereol. 2017;31(8):1254\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1729_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000209234","volume":"219","author":"AM Eghlileb","year":"2009","unstructured":"Eghlileb AM, Basra MKA, Finlay AY. The Psoriasis Family Index: preliminary results of validation of a quality of life instrument for family members of patients with psoriasis. Dermatology Basel. 2009;219(1):63\u201370.","journal-title":"Dermatology Basel"},{"issue":"4","key":"1729_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","volume":"51","author":"RG Langley","year":"2004","unstructured":"Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician\u2019s Global Assessment. J Am Acad Dermatol. 2004;51(4):563\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1729_CR10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2340\/00015555-1246","volume":"92","author":"NQ Phan","year":"2012","unstructured":"Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et\u00a0al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1729_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.sleep.2008.06.003","volume":"10","author":"RP Allen","year":"2009","unstructured":"Allen RP, Kosinski M, Hill-Zabala CE, Calloway MO. Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep). Sleep Med. 2009;10(5):531\u20139.","journal-title":"Sleep Med"},{"key":"1729_CR12","doi-asserted-by":"publisher","unstructured":"The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics [Internet]. [cited 2025 Dec 7]. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.2165\/00019053-199304050-00006","DOI":"10.2165\/00019053-199304050-00006"},{"issue":"18","key":"1729_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf9405","volume":"7","author":"KS Chun","year":"2021","unstructured":"Chun KS, Kang YJ, Lee JY, Nguyen M, Lee B, Lee R, et\u00a0al. A skin-conformable wireless sensor to objectively quantify symptoms of pruritus. Sci Adv. 2021;7(18):eabf9405.","journal-title":"Sci Adv"},{"issue":"2","key":"1729_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s13555-021-00660-3","volume":"12","author":"MG Lebwohl","year":"2022","unstructured":"Lebwohl MG, Soliman AM, Yang H, Wang J, Hagan K, Padilla B, et\u00a0al. Impact of risankizumab on PASI90 and DLQI0\/1 duration in moderate-to-severe psoriasis: a post hoc analysis of four phase 3 clinical trials. Dermatol Ther (Heidelb). 2022;12(2):407\u201318.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"1729_CR15","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s13555-025-01474-3","volume":"15","author":"B Strober","year":"2025","unstructured":"Strober B, Patel M, Kaldas MI, St. John G, Photowala H, Sima AP, et\u00a0al. Real-world skin clearance and quality of life with risankizumab in patients with psoriasis with moderate skin involvement and those eligible for systemic therapy per International Psoriasis Council classification. Dermatol Ther (Heidelb). 2025;15(9):2409\u201321.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6","key":"1729_CR16","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/bjd.12000","volume":"167","author":"BE Strober","year":"2012","unstructured":"Strober BE, Sobell JM, Duffin KC, Bao Y, Gu\u00e9rin A, Yang H, et\u00a0al. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label phase IIIB trial. Br J Dermatol. 2012;167(6):1374\u201381.","journal-title":"Br J Dermatol"},{"key":"1729_CR17","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.4507","volume":"103","author":"K Vlami","year":"2023","unstructured":"Vlami K, Pantelidi K, Dalamaga M, Karagianni F, theodoropoulos K, Papiris S, et\u00a0al. Psoriatic insomnia: a subjective and objective sleep evaluation. Acta Derm Venereol. 2023;103:4507.","journal-title":"Acta Derm Venereol"},{"issue":"22","key":"1729_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003816","volume":"95","author":"CY Wu","year":"2016","unstructured":"Wu CY, Chang YT, Juan CK, Shen JL, Lin YP, Shieh JJ, et\u00a0al. Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Medicine. 2016;95(22):e3816.","journal-title":"Medicine"},{"issue":"3","key":"1729_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/1346-8138.16620","volume":"50","author":"Y Mizutani","year":"2023","unstructured":"Mizutani Y, Kanai Y, Murotani K, Honma M, Higashiyama M, Kobayashi S, et\u00a0al. Treatment with brodalumab is not associated with improved sleep problems in real-life patients with plaque psoriasis: results of the ProLOGUE study. J Dermatol. 2023;50(3):319\u201326.","journal-title":"J Dermatol"},{"issue":"4","key":"1729_CR20","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s13555-018-0267-9","volume":"8","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Reich A, Steinhoff M, Beselin A, Kent T, Dossenbach M, et\u00a0al. Impact of ixekizumab treatment on itch and Psoriasis Area and Severity Index in patients with moderate-to-severe plaque psoriasis: an integrated analysis of two phase III randomized studies. Dermatol Therapy. 2018;8(4):621\u201337.","journal-title":"Dermatol Therapy"},{"key":"1729_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jdrv.2025.02.009","volume":"4","author":"M Samaniego","year":"2025","unstructured":"Samaniego M, Alonso M, Sohail N, Mostaghimi L. Sleep in dermatologic conditions: a review. JAAD Reviews. 2025;4:6\u201343.","journal-title":"JAAD Reviews"},{"issue":"2","key":"1729_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s13555-025-01342-0","volume":"15","author":"D Tha\u00e7i","year":"2025","unstructured":"Tha\u00e7i D, Ohtsuki M, Maul JT, Szegedi A, Luna PC, Lynde CW, et\u00a0al. Real-world effectiveness of Risankizumab in patients with moderate-to-severe psoriasis: interim analysis from the VALUE global prospective post-marketing observational study at 25 months. Dermatol Ther. 2025;15(2):381\u201394.","journal-title":"Dermatol Ther"},{"issue":"9","key":"1729_CR23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","volume":"25","author":"L Puig","year":"2011","unstructured":"Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007\u201311.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01729-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:18:34Z","timestamp":1779949114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01729-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1729"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01729-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors: Lev Pavlovsky has served as an investigator for Abbvie, Coherus, Novartis Pharmaceuticals Corporation, Janssen Biotech, Eli Lilly, and Bristol Myers Squibb and as an advisor, consultant, and\/or invited lecturer for Abbvie, Janssen Biotech, Novartis Pharmaceuticals Corporation, Pfizer Inc., Dexcel Pharma, Eli Lilly, Bristol Myers Squibb, Neopharm, and Boehringer Ingelheim. Yulia Valdman-Grinshpoun has served as a consultant, advisor, or speaker to AbbVie, Amgen, Boehringer Ingelheim, Dexcel pharma, Janssen, Eli Lilly, Neopharm, Novartis, Johnson & Johnson, Perrigo, Pfizer, Sanofi, Piere Fabre, MSD, BMS, Taro, Cellgen, and Amgen. Sari Murad has served as a consultant to Taro, Johnson and Johnson, Novartis, Pfizer, L\u2019Or\u00e9al, La roche posay, CeraVe, Abbvie, and Lilly. Eran Shavit has served as a consultant to AbbVie and has received research funding and speaker fees from AbbVie. Tali Czarnowicki served as a consultant, advisor, or speaker to Abbvie;\u00a0La Roche-posay;\u00a0Neopharm; Novartis; Rafa; Sanofi.\u00a0Naji Bathish and Yuri Shclar served as a consultant, advisor, or speaker to Novartis; Johnson & Johnson, Pfizer, BMS, LILY, TARO, ABBVIE. Liuqing Yang, Assaf Halperin, Shiran Naftalberg Blonder, Raanan Cohen, Alex Bleterman, Moran Barak, Inbal Piller Maor, and Sandra Goss are employees of AbbVie and own AbbVie stock. Hagit Matz and Igor Snast have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board (IRB) of Rabin Medical Center (0002\u201321-RMC), and the IRBs of all participating study sites (full list in Supplementary Table\u00a0S4). All participants provided informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}